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Abstract
Objective: The objective of this selective EBM review is to determine whether or not curcumin
can manage and prevent major complications for type 2 diabetics or even prevent the onset of
type 2 diabetes in pre-diabetics.
Study Design: Review of two English articles and one English/Italian article. Two were doubleblinded, randomized control trials (RCTs) and one was a controlled, therapeutic protocol registry
in which subjects were allowed to choose to be in the experimental group. All were published
after 2012.
Data Sources: Both RCTs and the controlled, registry study were found through PubMed.
Outcomes measured: This review assessed whether curcumin could delay the progression of
prediabetes to diabetes, prevent the onset of obesity and reduce the degree of vision loss in type 2
diabetics. The following were measured by tallying the number of subjects who developed type 2
diabetes, measuring waist circumference, and comparing scores on the Snellen eye chart
respectively.
Results: With regards to preventing the onset of type 2 diabetes, the ARR demonstrated that
there was a 16% absolute decrease in the risk of developing it, but it is also not a large risk
reduction since most of the subjects on placebo did not progress to type 2 diabetes anyway. The
difference in the number of subjects who progressed to type 2 diabetes was still statistically
significant. The difference in waist circumference was not statistically significant, but only
subjects taking curcumin had any reduction in their waist circumference. The difference in the
degree of vison loss between control and experimental groups was statistically significant, but
the sample size was too small to assume the results would be generalizable to the larger
population.
Conclusions: These studies demonstrate that curcumin is beneficial with no significant adverse
reactions. The evidence is still inconclusive because of the following limitations; study duration
of less than a year, sample populations that were based outside of the US, and small sample size.
Future studies should include a more diverse study population and observe the effects of
curcumin for a longer period of time.
Key words: “prediabetes”, “type 2 diabetes”, “curcumin”
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INTRODUCTION
Diabetes mellitus refers to a group of metabolic disorders that are characterized by
hyperglycemia.1 Type 2 diabetes mellitus(T2DM) is a metabolic condition in which blood
glucose levels in the body stay elevated due to insulin resistance and impaired insulin secretion
and utilization.1 In 2015, Diabetes was the 7th leading cause of death.2 No single cause of Type 2
diabetes has been identified, but many studies support that insulin resistance is the leading factor,
since it precedes the impairment in insulin secretion that ultimately leads to diabetes.1
Insulin resistance is the inability of insulin to act on target tissues such as skeletal
muscle. It is the predominant feature of T2DM 1 and manifests in patients who are obese and
genetically susceptible. Early on, glucose levels and tolerance are normal because the beta cells
in the pancreas are able to compensate for the insulin resistance by increasing their insulin output
to stimulate glucose-uptake by skeletal muscle. However, as insulin resistance persists, the beta
cells can no longer keep up with the demand for insulin, resulting in postprandial hyperglycemia.
As insulin secretion declines further, fasting hyperglycemia manifests since there is not enough
insulin to suppress gluconeogenesis in the liver. A vicious cycle develops in which this chronic
state of hyperglycemia continues to impair beta cell function, prolonging the hyperglycemia.
Visceral obesity in particular1, and a lack of physical activity are the two most significant
environmental factors in the development of T2DM. 3 Obesity is known to decrease beta cell
sensitivity to glucose and cause resistance to insulin-mediated glucose uptake.3; 12.2% of all
adults aged 18 years or older in the US have type 2 diabetes and 87.5% of them were overweight
or obese.2 Weight loss alone can be enough to reverse these effects and normalize glucose
levels.2 Inflammation likely plays a role too; factors released from adipose tissue called
adipokines stimulate inflammatory activity which correlates to insulin resistance.3 Inflammation
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is also the likely link between T2DM and atherosclerosis; there are increased levels of
inflammatory markers in patients with T2DM such as C-reactive protein, and tumor necrosis
factor-alpha. 3 Lifestyle interventions can decrease the levels of these inflammatory markers. 3
Prediabetes is a term that is used to describe a state of higher than normal blood glucose
levels that put patients at risk for developing type 2 diabetes and cardiovascular disease.4 In the
available data from 2015, 33.9% of all adults aged 18 years or older in the US have prediabetes.2
It is indicated by an A1c of 5.7%-6.4%, a fasting blood glucose level of 100-125 mg/dl, and a 2
hour glucose level of 140-199 mg/dl following the oral glucose tolerance test.4 Like diabetic
patients, they may also be asymptomatic so routine lab studies are crucial in identifying
hyperglycemia early on. Identifying pre-diabetic patients is key since they can implement
lifestyle changes, such as weight loss, that can lower their risk of developing T2DM.
Management of T2DM is difficult since the degree of insulin resistance and onset of
impaired insulin secretion varies from patient to patient.1 For example, it is not uncommon to
start patients on insulin with metformin because many patients may already have long-standing
diabetes.1 Metformin is endorsed by the American Diabetes Association as a low cost, 1st line
therapy since it can help promote weight loss and even lower lipid levels.1 If metformin alone is
not enough to reach the blood glucose target of ≤ 200 mg/dL, other agents are added on such as
GLP-1 receptor agonists.
Complications related to T2DM not only impose major health consequences, but also
comprise a large portion of the financial burden patients face; a type 2 diabetic spends an average
of $85,500 over his or her lifetime on doctor visits, medications, and supplies;5 53% of this is
typically spent on treating complications related to their diabetes.5 Since many of these are
related to inflammation, curcumin is being sought as a natural preventative tool against diabetes
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because it is known to be anti-inflammatory with anti-diabetic properties.6, 7 It is also a low-cost
option that is potentially safe for long-term use. 6 Diabetics have 30.3 million healthcare visits a
year 8 so physician assistants will undoubtedly encounter these patients in practice and will do a
great service to them by offering them remedies that can relieve the burden of their illness.
OBJECTIVE
The objective of this systematic review is to determine whether or not curcumin can
manage and prevent major complications for type 2 diabetics or even prevent the onset of type 2
diabetes in pre-diabetics.
METHODS
This systematic review evaluated 3 research studies that fit the inclusion criteria of
evaluating adults 18 years of age and older with prediabetes and type 2 diabetes. Any study that
dealt with pediatric patients or Type 1 diabetes were excluded. The research articles were found
through PubMed and were published in peer-reviewed journals from 2012-2014. Two of the
articles were published in English and the third article was originally published in Italian. The
articles were found using the key words “prediabetes”, “type 2 diabetes”, and “turmeric”. Two
of the studies were double-blinded, randomized controlled studies and the third study was a
controlled, therapeutic protocol registry in which subjects were allowed to choose the
management protocol they were willing to adhere to for the duration of the study.
The articles were chosen for this review based on their relevance to the clinical objective
above and whether they discussed patient oriented evidence that matters (POEMs). Each of the
studies assessed how effective curcumin was in delaying the onset of complications related to
diabetes and the onset of T2DM itself in pre-diabetics. Of the two double-blinded, randomized
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studies, one compared pre-diabetics taking curcumin for 9 months and the other compared
diabetics taking curcumin for 6 months to control groups taking placebo. The therapeutic
protocol registry compared diabetics taking curcumin as an adjunct to their current management
regimen to diabetics who did not add curcumin. ANOVA and p-values were used or reported in
the selected articles.
Table 1-Demographics and characteristics of included studies
Study

Type

# of
Pts

Age
(yrs)

Inclusion Criteria

Exclusion
Criteria

W/D

Interventions

Chuengsamarn S.,
2012 (1)6

Double
blinded,
RCT

240

≥ 35

Pre-diabetics age ≥ 35
who fit one of these
three criteria
- fasting glucose
between 100-124
mg/dL
-2hr post-glucose load
after oral glucose
tolerance test was 140199 mg/dL
-HbA1C was between
5.7-6.4%

3

Three 250 mg
capsules of
Curcuminoid
BID x 9 months

Chuengsamarn S.,
2014 (2)7

Double
blinded,
RCT

240

≥ 35

Type 2 diabetics age ≥
35 who fit one of these
3 criteria
-fasting glucose was ≥
126 mg/dL
-2hr post-glucose load
after oral glucose
tolerance test was ≥
200 mg/dL.

0

Three 250 mg
capsules of
Curcuminoid
BID x 6 months

Steigerwalt, R.,
2012 (3)9

Controlled
study

77

No
age
specif
ied

Type 2 diabetics
-with diabetic
retinopathy
-BMI of 24-26
-with diabetes for ≥ 5
years
-who had been stable
for at least 3 months
on the standard
management protocol
of diet, exercise, and
oral meds prior to the
start of the study.

-Any subject
diagnosed
with type 2
diabetes
-Any
subjects
receiving
other herbal
medicines
-Any
subjects
taking oral
hypoglycem
ic agents.
-Prediabetics
- Anyone
receiving
other herbal
medicines
- Anyone
taking oral
hypoglycem
ic agents
-Concurrent
metabolic
disorders
-Previous
use of
insulin
-Clinical
signs of
atherosclero
sis
-History of
diabetic
ulcers

0

One 500 mg
Meriva tablet
(equivalent to
100mg of
curcumin) BID
x 4 weeks
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OUTCOMES
One of the double-blinded studies assessed whether curcumin could delay the progression
of prediabetes to diabetes by tallying the number of subjects from the curcumin-treated and
placebo-treated groups who were diagnosed with type 2 diabetes mellitus. The other assessed
whether curcumin could prevent the onset of obesity by comparing the waist circumference of
subjects from the curcumin-treated and placebo-treated groups. The therapeutic protocol registry
study assessed whether curcumin could improve visual acuity in patients with diabetic
retinopathy by using the Snellen eye chart as a means of comparison.
RESULTS
Both studies by Chuengsamarn et al. from 2012 and 2014 performed data analysis on an
intention to treat basis such that those that were lost to follow-up were still included in the
analysis of the groups to which they were initially randomized to; however, no data was
available about those subjects lost to follow-up. No worse case analysis were performed on the
subjects who dropped out.6,7 The researchers in the study by Steigerwalt et al. did not mention
whether their data analysis was done on an intention to treat basis, but they reported that all
subjects in the control and experimental groups completed follow-up without any drop-outs. 9
Researchers from all the studies report that all baseline parameters for the control group and the
group taking curcumin products were not statistically different.6,7,9
In both of the double-blinded studies by Chuengsamarn et al, researchers eliminated
confounding variables by educating subjects on the diet and exercise protocols they should
follow for 3 months prior to randomization and excluding anyone who was taking other oral
medications as mentioned in Table 1. Subjects were instructed to take 3 capsules with blinded
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labels of curcumin or placebo twice a day for 6 months7 or 9 months6; the dosages are reported in
Table 1. To ensure compliance, researchers had patients bring their capsules to their follow-up
visits at 3, 66,7 and 9 months6.
The double-blinded controlled study by Chuengsamarn et al. from 2012 assessed whether
or not curcumin could prevent pre-diabetics from developing type 2 diabetes. Out of 240 subjects
that were enrolled, 237 subjects were randomized into the curcumin and placebo treated groups
with 116 subjects in the control group and 119 subjects in the curcumin group. At the end of
their study, no subjects taking curcumin as part of their diet and exercise regimen developed type
2 diabetes, while 16% of the placebo-treated subjects were newly diagnosed with type 2 diabetes.
Since the outcome of developing type 2 diabetes or not was dichotomous data, the
treatment effects of curcumin were able to be calculated from this study as reported in table 2
below. These calculations were based on data with a p-value of 0.001 which indicates that the
following estimates of the treatment effect are statistically significant.
Table 2: Treatment effects of curcumin from Chuengsamarn et al.6
RRR
19%

ARR
16%

NNT
-1/0.16=-7

The RRR demonstrates that pre-diabetic subjects taking curcumin had a 19% lower risk
of progressing to type 2 diabetes compared to the subjects taking placebo. The ARR
demonstrates that pre-diabetic subjects taking curcumin had a 16% absolute decrease in their risk
of developing type 2 diabetes. However, the RRR and ARR values also indicate that the
reduction in risk compared to those on placebo wasn’t that large since the majority of subjects
taking placebo also did not progress to type 2 diabetes. This negative NNT value means that for
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every 7 pre-diabetic patients who are given curcumin as a daily supplement for at least 9 months,
1 less pre-diabetic patient will develop type 2 diabetes, compared to the control group. Overall,
the difference between the placebo and curcumin treated groups was statistically significant, but
the level of risk reduction was not so large.
The 2014 study by Chuengsamarn et al.7 and the study by Steigerwalt et al.9 assessed
whether curcumin could help reduce the risk of complications in patients with type 2 diabetes.
Chuengsamarn et al.7 evaluated whether curcumin could prevent the onset of abdominal obesity,
a major atherogenic risk factor and Stiegerwalt9 evaluated whether curcumin could reduce the
degree of vision loss from diabetic retinopathy. These results were published as ranges, instead
of discrete values so they could not be converted to dichotomous data for this review.
Chuengsamarn et al.7 assessed abdominal obesity by waist circumference which was
measured with tape in the horizontal plane midway between the inferior margin of the wrist and
the superior border of the iliac crest. While the researchers were able to show that curcumin
helped improve the subjects’ metabolic profile7, they found that the decrease in waist
circumference in the curcumin treated group from 90.7 to 88.2 cm7 was not statistically
significant as evidenced by a p-value >0.05 for that data. Despite the reductions in waist
circumference and abdominal obesity in the subjects taking curcumin, the authors acknowledged
that they could not prove whether this reduced their risk of atherosclerosis. However, it is
noteworthy that none of the subjects in the placebo-treated group had a decrease in their baseline
waist circumference.7
The study by Steigerwalt et al9 sought to determine whether curcumin could help reduce
the degree of vision loss in patients with diabetic retinopathy, a major cause of blindness in this
population. 9 They tested a product called Meriva, which is curcumin complexed with
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phosphatidylcholine that is known to have better bioavailability than the natural product. 9,10
Researchers eliminated confounding variables by only accepting diabetics who did not have any
atherosclerotic disease; the rest of the inclusion criteria is listed in Table 1.
In this study, subjects were offered 2 management plans and they were able to choose
which they would like to follow for the duration of the study. The control group of 39 subjects
agreed to follow the standard management plan of diet, exercise, and oral medications, while the
experimental group of 38 subjects added Meriva to the standard management plan for 4 weeks.
Subjects were instructed to take a 500mg Meriva tablet twice a day before meals, corresponding
to a daily dose of 200mg of curcumin.9
At the end of the 4 week study, subjects taking Meriva had improved visual acuity as
evidenced by changes in the Snellen eye scale. Both groups initially had moderate vision loss
defined as a score of 20/80-20/160.9 The group taking Meriva were the only subjects whose
visual acuity improved to a score of 20/32-20/78, which reflects mild vision loss.9 Visual acuity
in the control group improved, but their scores were still within the range of moderate vision
loss. The researchers report that they used ANOVA to evaluate their before and after results, but
they did not publish their test statistic, F. Regardless, these results were statistically significant as
evidenced by a p-value of <0.025 for that data.9
The 2012 and 2014 studies by Chuengsamarn et al.6,7 concluded that curcumin could be
safely used by patients for at least 9 months without serious adverse effect based on their
findings that only 2 subjects had constipation, 1 subject had vertigo, and another had nausea.6,7
The researchers mention that their results are reliable because there were no issues of compliance
between the placebo and curcumin treated groups since the number of capsules subjects in both
groups had remaining at each follow-up visit were similar.6,7
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Table 3: Summary of the statistical significance of the outcomes in the included studies
Chuengsamarn et al, 2012

Chuengsamarn et al, 2014

Steigerwalt et al, 2012

p<0.001

p>0.05

p<0.025

DISCUSSION
This systematic review found that curcumin certainly had a beneficial effect on subjects,
but, not all of the results demonstrated a significant difference between subjects taking curcumin
from those who did not. Furthermore, despite the researchers’ efforts to avoid confounding
variables, the results from these studies are not generalizable since the subjects did not hail from
the US and these studies did not use the same curcumin product. None of the studies ran for even
a year, so it is difficult to conclude that the effects of curcumin were long-lasting.
In both studies by Chuengsamarn et al6,7, the researchers tried to keep all subjects on the
same routine for exercise and diet to limit variability with daily reminders by nutritionists so this
helps to make the results generalizable to some extent. However, the subjects were all residents
of a small province in central Thailand so it is uncertain whether subjects in the US who hail
from different racial backgrounds and ethnicities will experience the same metabolic effects.
Steigerwalt et al9 did not report any patient characteristics, such as the ethnicity or geographical
region they hailed from, which makes it difficult to assess the generalizability of their results.
In these studies, subjects were followed for less than a year so it is uncertain how
sustainable the effects of curcumin are. For example, despite the results in Chuengsamarn et al7
that no pre-diabetic taking curcumin developed type 2 diabetes, there is still a possibility of
developing type 2 diabetes in the long-term despite taking curcumin.7 Even though Steigerwalt,
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et al boast that their study design optimizes compliance since their subjects chose the protocol
they were willing to follow9, the duration of their study was only 4 weeks so it is unknown
whether the subjects would adhere to the regimen long-term. In addition, their study was not
double-blinded since the subjects were able to choose which protocol they wanted to follow and
the researchers knew which subjects chose what protocol. Thus, there is a high risk of bias here
since the subjects knew that they were in the experimental group and this could have influenced
their behavior during the study.
The results from this systematic review are also not generalizable because Steigerwalt et
al tested a type of curcumin that is not the same as the natural product. Meriva is a lecithin
delivery system of curcumin that offers better bioavailability because it is complexed with a
phospholipid, phosphatidylcholine, which helps to fixate the otherwise polar curcumin within the
inner lipid compartment of the cell membrane.10 This helps to increase its plasma bioavailability
since phospholipids are easily exchanged between cell membranes and extracellular fluid.10 The
degree to which vision improved in subjects taking Meriva compared to subjects who did not add
it to their routine was statistically significant, but it is unknown whether diabetics taking natural
curcumin would experience the same degree of improvement in their retinopathy. Furthermore,
the sample size of only 77 participants was too small for the results to be representative of the
larger diabetic population and may have overestimated the treatment effect.
Turmeric has been used medicinally for centuries in Hindu medicine for its antiinflammatory and antioxidant effects.11 This makes it invaluable in the management of chronic
inflammatory states, such as type 2 diabetes, that make patients prone to developing obesity,
atherosclerosis and microvascular disease, such as diabetic retinopathy.7,9 It is generally
available in the US in capsule form and most manufacturers instruct buyers to take 1-3 500mg
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capsules daily with or without food. Curcumin is the active compound of turmeric that is often
studied in clinical trials.11 Few adverse reactions have been reported with turmeric in the US,
even at high dosages.11 Most of the reported side effects have been GI-related with rare cases of
anaphylaxis.11 Turmeric has a high concentration of oxalate so it may increase the risk of kidney
stones in those who are susceptible, but there have been no reports of this thus far. 11
CONCLUSION
Based on this review, the evidence is still inconclusive as to whether or not curcumin can
manage and prevent major complications for type 2 diabetics or even prevent the onset of type 2
diabetes in pre-diabetics. The outcomes are promising, but the results were based on a timeframe of less than a year so it cannot be assumed that the outcomes were sustainable long-term.
Future studies on curcumin should be done on a larger nationwide scale where US
residents from all states with various demographics would be included. One limitation with these
studies is that their results are based on subjects who were all from the same ethnicity and living
in the same region. More research must be done to assess whether curcumin would have a
beneficial effect on people of different ethnicities and whether each ethnic group would
experience a benefit to the same degree. Cohort studies of pre-diabetics and diabetics taking
curcumin with their daily regimen can be useful for assessing whether patients can tolerate longterm daily intake without significant adverse reactions and whether the effects of curcumin are
sustained long-term with daily intake.
Overall, this review demonstrates that curcumin can have a positive impact on diabetics
as a lifestyle intervention. It may help reduce visceral obesity, which will decrease their risk of
cardiovascular and inflammatory complications and improve their quality of life.
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